Neumora Therapeutics Inc

NMRA is basing in an early Stage 1 consolidation with price forming higher highs and higher lows above the short-term EMAs, signaling stabilization and a foundation for a trend reversal. Short-term EMAs (9/21) have shifted to support and price is holding above them, offering a favorable pullback entry. The active Higher Highs & Higher Lows pattern indicates demand dominance and a bullish medium-term stance, despite the long-term downtrend persisting.

• ↑Up to six clinical data readouts next 18 months (NMRA-511, NMRA-215)
• ↑$217.6M cash supports operations into Q3 2027
• ↓Navacaprant program discontinued after Coastal 1 failed to show statistical benefit